Napo Pharmaceuticals has told covered entities how they can continue to buy Mytesi, an antidiarrheal for patients living with HIV/AIDS who take antiretroviral drugs, at its 340B price.

Napo Pharmaceuticals Tells Entities How They Can Keep Getting 340B Price on Limited-Distribution Drug

Napo Pharmaceuticals yesterday posted a public notice to 340B covered entities about how to obtain 340B pricing on Mytesi, an antidiarrheal for patients living with HIV/AIDS who take antiretroviral drugs.

Napo said in the notice on the U.S. Health Resources and Services Administration (HRSA) website that it was limiting distribution of the drug “to help ensure that patients being treated with Mytesi receive high quality supportive care and therapeutic adherence.” The company has designated three specialty pharmacies for Mytesi: CVS Specialty Pharmacy, AllianceRx Walgreens Prime, and Accredo Specialty Pharmacy.

“340B covered entities wishing to obtain Mytesi for their patients at the 340B price should contact one of these three specialty pharmacies to arrange for the pharmacy to service the covered entity as a contract pharmacy and dispense Mytesi directly to the covered entity’s patients,” the company said.

Editor at Large | Website | + posts